Navigation Links
MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products

WILMINGTON, Delaware, December 16 /PRNewswire/ -- While many of the pharma companies are struggling to outsource their accurate forecast models for new and inmarket drugs, MarketsandMarkets on the other hand provides integrated patient-based forecast solutions to various players. These pharma forecasting solutions are designed for phase I, phase II, as well as phase III. These have a substantial impact on pricing, launch, product life cycle management, market entry strategy, manufacturing planning, sales force, promotion, and planning. The leading pharma companies now endorse the forecast solution provided by MarketsandMarkets as the accurate forecast model, comprising of significant cost benefit analysis for an annual contract basis. The forecasts are based on epidemiology and actual patients on drugs. The primary and secondary research analytics underlying the forecast include:

    - Epidemiology analysis
    - Treated patients best fit trending
    - Polypharmacy ratio analysis
    - Competitive landscape analysis
    - Analogue analysis for uptake, time to peak, and generic erosion
    - Conjoint / discrete choice / attribute analysis
    - Calibration based on actual sales and impact of various events

The treated patient pool potential is determined by prevalence, incidence, diagnosis, treatment, cure, and mortality rate. The treated patient pool is also back-calculated simultaneously from historic and present product sales. Trending and smoothening takes into account seasonality and the impact of other events on sale. The conjoint / discrete choice analysis uses primary research to estimate peak patient share for new products. In absence of primary research due to budget / time constraints, an attribute analysis is done using secondary research and consumer inputs to estimate peak patient share for new products.

The peak patient share calculation mechanism is calibrated based on shares of existing products. Ratio of treated patient pool, based on patient on products and epi, gives polypharmacy ratio. Analogues are identified based on disease area, TPP, MoA, order of entry, and market dynamics to estimate time to peak, shape of uptake curve, generic erosion, and impact of other events. Share exchange / cannibalization is done based on fair-share approach or inputs from brand team along with secondary and primary research.

Simple and transparent VB- and Excel-based forecast models: models are developed based on forecast complexity and the functional need of end-user. Our team has expertise in designing and developing VB- and Excel-based forecast / market models.

Strong quality checks: - quality checks are built up at each stage to ensure foolproof estimates, including triangulation of epi data from multiple sources, calibration based on polypharmacy and actual historic sale, calibration of peak patient share estimation model or peak patient share based on share. Quality checks embedded in the Excel / VB formula in the forecast model.

We have strong team of analysts with experience in executing advanced forecasting projects for both pipeline and in-market products for the top pharma companies globally.

    For more details, click on:

About MarketsandMarkets

MarketsandMarkets is a research and consulting firm that publishes 120 market research reports per year. Each strategically analyzed report contains 250 pages of valuable market data, including more than 100 market data summary tables and in-depth, five-level segmentation for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports also analyze about 200 patents, over 50 companies and micro markets that are mutually exclusive and collectively exhaustive. Browse all our 120 titles at

    Ms. Sunita
    108, West 13th Street,
    Wilmington, DE, 19801
    County of New Castle
    Tel: +1-888-989-8004

SOURCE MarketsandMarkets

SOURCE MarketsandMarkets
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MarketsandMarkets: Global Neurostimulation Market Worth US$10.2 Billion by 2014
2. MarketsandMarkets: Global Home health Care Market Worth US$159.6 Billion by 2014
3. MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014
4. MarketsandMarkets: Global Biomarker Market Worth US$ 20.5 Billion by 2014
5. MarketsandMarkets: Top Ten Medical Device Technologies Market Worth $454.3 Billion by 2014
6. Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential
7. EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content
8. InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery
9. Amedisys Selects MetricStream for Integrated Enterprise-wide GRC
10. Health Integrated Announces Turnkey Model of Care Program for Special Needs Health Plans
11. Glide Health Corporation and Integrated Medical Professionals Announce Partnership to Deploy the Glide Mobile Health Platform to Over One Million Patients and Over 100 Physicians in 50 Locations
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
Breaking Medicine Technology: